Antimicrobial stewardship-the state of the art in 2011: Focus on outcome and methods

Infection Control and Hospital Epidemiology

Volumn 33, Issue 4, 2012, Pages 331-337

  Mcgowan, John E ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CLOSTRIDIUM DIFFICILE INFECTION; COST CONTROL; DRUG COST; DRUG USE; EVIDENCE BASED MEDICINE; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICAL EDUCATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SAFETY; PRESCRIPTION; PROSPECTIVE PAYMENT; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-INFECTIVE AGENTS; COST CONTROL; DRUG COSTS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SAFETY;

EID: 84858804305     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/664755     Document Type: Article

References (59)

1. McGowan JE Jr, Finland M. Usage of antibiotics in a general hospital: effect of requiring justification. J Infect Dis 1974;130: 165-168.
2. Hampton JR. The end of clinical freedom. Br Med J (Clin Res Ed) 1983;287:1237-1238.
3. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistinresistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593-599.
4. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:257-263.
5. Wise R. The urgent need for new antibacterial agents. J Antimicrob Chemother 2011;66:1939-1940.
6. Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011;53(suppl 1):S4-S7.
7. Liew YX, Lee W, Kwa AL, Lye DC, Yeo CL, Hsu LY. Inappropriate carbapenem use in Singapore public hospitals: opportunities for antimicrobial stewardship. Int J Antimicrob Agents 2011;37: 87-88.
8. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010;51:895-903.
9. Carlet J, Collignon P, Goldmann D, et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011;378: 369-371.
10. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am 2011;25:245-260.
11. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011;6(suppl 1):S4-S15.
12. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance? New Horiz 1996;4:370-376.
13. Reuben DB, Cassel CK. Physician stewardship of health care in an era of finite resources. JAMA 2011;306:430-431.
14. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol 2011;32:367-374.
15. Van Schooneveld T, Miller H, Sayles H, Watkins K, Smith PW. Survey of antimicrobial stewardship practices in Nebraska longterm care facilities. Infect Control Hosp Epidemiol 2011;32: 732-734.
16. Septimus EJ, Owens RC Jr. Need and potential of antimicrobialstewardship in community hospitals. Clin Infect Dis 2011; 53(suppl 1):S8-S14.
17. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011;38:16-26.
18. Davey P, Sneddon J, Nathwani D. Overview of strategies for overcoming the challenge of antimicrobial resistance. Expert Rev Clin Pharmacol 2010;3:667-686.
19. Thakkar K, Gilchrist M, Dickinson E, Benn J, Franklin BD, Jacklin A. A quality improvement programme to increase compliance with an anti-infective prescribing policy. J Antimicrob Chemother 2011;66:1916-1920.
20. Toth NR, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. Am J Health Syst Pharm 2010;67:746-749.
21. White AR. Effective antibacterials: at what cost? the economics of antibacterial resistance and its control. J Antimicrob Chemother 2011;66:1948-1953.
22. Slain D, Sarwari AR, Petros KO, et al. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting. Crit Care Res Pract 2011;2011:416426.
23. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44: 159-177.
24. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005:CD003543.
25. Jacob JT, Gaynes RP. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther 2010;8:893-902.
26. Ohl CA, Dodds Ashley ES. Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis 2011;53(suppl 1):S23-S28.
27. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706.
28. Fishman N. Antimicrobial stewardship. Am J Med 2006;119: S53-S61; discussion S62-S70.
29. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(suppl 2):S112-S121.
30. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-239.
31. Gandhi TN, DePestel DD, Collins CD, Nagel J, Washer LL. Managing antimicrobial resistance in intensive care units. Crit Care Med 2010;38:S315-S323.
32. Paul M, Andreassen S, Tacconelli E, et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 2006;58:1238-1245.
33. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851-4863.
34. Joo EJ, Kang CI, Ha YE, et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection 2011;39:309-318.
35. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011;66:1223-1230.
36. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broadspectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011;66: 2168-2174.
37. Chiu CH, Michelow IC, Cronin J, Ringer SA, Ferris TG, Puopolo KM. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J 2011;30: 273-278.
38. Willemsen I, Groenhuijzen A, Bogaers D, Stuurman A, van Keulen P, Kluytmans J. Appropriateness of antimicrobial therapy measured by repeated prevalence surveys. Antimicrob Agents Chemother 2007;51:864-867.
39. Lan CK, Hsueh PR, Wong WW, et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect 2003;36:182-186.
40. Lee SO, Lee ES, Park SY, Kim SY, Seo YH, Cho YK. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25:832-837.
41. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006;27:155-169.
42. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006;42:778-784.
43. Lipworth AD, Hyle EP, Fishman NO, et al. Limiting the emergence of extended-spectrum b-lactamase-producing Enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006;27:279-286.
44. Troughton JA, Millar G, Smyth ET, Doherty L, McMullan R. Ciprofloxacin use and susceptibility of gram-negative organisms to quinolone and non-quinolone antibiotics. J Antimicrob Chemother 2011;66:2152-2158.
45. Cook PP, Rizzo S, Gooch M, Jordan M, Fang X, Hudson S. Sustained reduction in antimicrobial use and decrease in methicillin-resistant Staphylococcus aureus and Clostridium difficile infections following implementation of an electronic medical record at a tertiary-care teaching hospital. J Antimicrob Chemother 2011;66:205-209.
46. McGowan JE Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001;7:286-292.
47. Harbarth S, Graves N. Health economic analysis in infection control. In: Scientific Programme of the First International Conference on Prevention and Infection Control. Geneva, June 30-July 2, 2011, p 29.
48. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasiexperimental studies in infectious diseases. Clin Infect Dis 2004; 38:1586-1591.
49. Cooke FJ, Holmes AH. The missing care bundle: antibiotic prescribing in hospitals. Int J Antimicrob Agents 2007;30:25-29.
50. Dortch MJ, Fleming SB, Kauffmann RM, Dossett LA, Talbot TR, May AK. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcareassociated infections. Surg Infect (Larchmt) 2011;12:15-25.
51. Barie PS. SCIP to the loo? Surg Infect (Larchmt) 2011;12: 161-162.
52. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria? Clin Infect Dis 2006;43(suppl 2): S57-S61.
53. Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry 2011;72:412-413.
54. Martins CL, Garly ML, Bale C, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008;337:a661.
55. Haber M, Levin BR, Kramarz P. Antibiotic control of antibiotic resistance in hospitals: a simulation study. BMC Infect Dis 2010; 10:254.
56. Vernaz N, Huttner B, Muscionico D, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011;66:928-935.
57. Regev-Yochay G, Raz M, Dagan R, et al. Reduction in antibiotic use following a cluster randomized controlled multifaceted intervention: the Israeli judicious antibiotic prescription study. Clin Infect Dis 2011;53:33-41.
58. Pires dos Santos R, Jacoby T, Pires Machado D, et al. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. Infect Control Hosp Epidemiol 2011;32:584-590.
59. Achhra AC, Phanuphak P, Amin J. Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS 2011; 6:258-265.